Avestar Capital’s Supernus Pharmaceuticals SUPN Stock Holding History

Avestar Capital’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-235	Closed	-$7K	–	746
2019 Q2	$7K	Hold	235	–	–	﹤0.01%	555
2019 Q1	$8K	Hold	235	–	–	0.01%	510
2018 Q4	$7K	Hold	235	–	–	﹤0.01%	495
2018 Q3	$11K	Hold	235	–	–	0.01%	453
2018 Q2	$14K	Hold	235	–	–	0.01%	415
2018 Q1	$10K	Hold	235	–	–	0.01%	429
2017 Q4	$9K	Buy	+235	New	+$9.29K	0.01%	469

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

ACM

Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return

Avestar Capital's SUPN Position: Q3 2019 in Review

Avestar Capital sold out of Supernus Pharmaceuticals (SUPN) in Q3 2019, closing a stake of 235 shares — an estimated $7K sold.

Avestar Capital first reported a position in SUPN in Q4 2017 and held it in 7 quarters. The position peaked at $14K in Q2 2018. 243 funds tracked by Wall St. Rank hold SUPN as of Q3 2019.

Avestar Capital reported no remaining Supernus Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Avestar Capital sold 235 Supernus Pharmaceuticals shares in Q3 2019, an estimated $7K.
Avestar Capital first reported a position in Supernus Pharmaceuticals in Q4 2017 and held it in 7 quarters.
Avestar Capital's Supernus Pharmaceuticals position peaked at $14K in Q2 2018.
243 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2019.

Based on Avestar Capital's 13F filing for Q3 2019, filed 14 Nov 2019.